Gilead, Hookipa in vector deal for HBV and HIV

Hookipa Biotech AG (Vienna, Austria) granted Gilead Sciences Inc. (NASDAQ:GILD) exclusive, worldwide rights to use its TheraT and Vaxwave arenavirus-based vector technologies to develop immunotherapies for HBV and HIV.

Hookipa is to receive $10 million up front and will be eligible for more than $400 million in milestones, plus royalties. Gilead will provide all R&D funding. Hookipa will manufacture arenavirus-based vectors for Gilead, and the companies will jointly develop therapies for HBV and HIV...